Skip to content

Addiction Science & Clinical Practice

2 papers in the library · 152 citations · publishing 2015-2022

Papers

Designer drugs 2015: assessment and management

Addiction Science & Clinical Practice March 11, 2015 Michael F. Weaver, John A. Hopper, Erik W. Gunderson 135 citations

Designer drugs, marketed as 'legal highs,' include substituted cathinones (e.g., mephedrone, methylone, MDPV), synthetic cannabinoids (e.g., Spice), and synthetic hallucinogens (e.g., 25I-NBOMe). Their availability changes rapidly to evade legal controls and detection. Young adults are the main users, with growing use in the military. Acute toxicity frequently causes severe psychiatric and medical effects such as anxiety, agitation, psychosis, and tachycardia, and deaths have been reported for each drug type. Clinicians should consider these drugs when evaluating substance use in young adults or patients with acute neuropsychiatric symptoms. Treatment of acute intoxication is supportive, while long-term treatment of designer drug use disorder lacks evidence-based guidance.

Coping motives mediate the relationship between PTSD and MDMA use in adolescents with substance use disorders

Addiction Science & Clinical Practice September 4, 2022 Lukas Andreas Basedow, Melina Felicitas Wiedmann, Veit Roessner et al. 17 citations

Adolescent patients with both post-traumatic stress disorder (PTSD) and substance use disorders (SUDs) reported more frequent past-year use of MDMA (ecstasy) than those with SUD alone or with traumatic experiences but no current PTSD. No such differences appeared for tobacco, alcohol, cannabis, or stimulants. The link between PTSD and higher MDMA use was partly explained by using the drug to cope with mental health symptoms. This suggests a specific coping mechanism for MDMA, possibly due to its unique psychoactive effects, rather than a general pattern of self-medication across all substances.